Pliant Therapeutics (PLRX) said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.
Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.
The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.
The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.
Price: 1.65, Change: +0.02, Percent Change: +1.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。